Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

NCT07202884 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07202884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07202884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Recruiting
Start date
September 30, 2025
Completion date
March 31, 2028
Enrollment
1,000 (estimated)
Sites
136

Conditions

As the registry lists them; a condition with its own page is linked.

urinary incontinence,stress